Bloom Science welcomes Dr. Grace Colón to its Board of Directors as Chair

– USA, CA –  Bloom Science, Inc., a clinical-stage, central nervous system (CNS) company focused on discovering and developing breakthrough therapeutics that target the Gut-Brain Axis, today announced the appointment of Dr. Grace Colón (Ph.D.) as Chair of its Board of Directors, effective immediately.

About Dr. Grace E. Colón

A distinguished scientist and leading executive in biotechnology, Dr. Colón will lend her business, scientific, clinical, and operational expertise to help Bloom Science in an exciting stage of research and development of new diagnostics and transformative medicines for patients with complex neurological disorders.

Dr. Colón has over 25 years of experience in biopharma, genomics, diagnostics, healthcare, industrial microbiology/biotechnology, synthetic biology, venture capital, management consulting, and entrepreneurship. Most recently, she was CEO and President of InCarda Therapeutics from 2013 to 2022, where she led the company from a seed-stage start-up to one with a best-in-class inhaled cardiovascular disease therapy being evaluated in a pivotal Phase 3 trial and a growing pipeline. She serves on the boards of CareDx, Voyager Therapeutics, the MIT Corporation (MIT’s Board of Trustees), and the Biotechnology Innovation Organization (BIO). She is also the Executive Chair (formerly CEO) of ProterixBio. Formerly, Dr. Colón held senior executive roles at Intrexon Corporation, Gilead Sciences, and Affymetrix. She was a partner at New Science Ventures, a New York-based venture capital firm, and served on the boards of Paradigm Diagnostics (acquired by Exact Sciences), PerceptiMed, and Cocoon Biotech and on the Advisory Board of the Miller Center for Social Entrepreneurship at Santa Clara University. Earlier in her career, Dr. Colón was a management consultant at McKinsey & Company and an engineer at Merck.

She received her Ph.D. in chemical engineering from the Massachusetts Institute of Technology, where she was a National Science Foundation Fellow. She also holds an undergraduate degree in chemical engineering from the University of Pennsylvania.

About Bloom Science

Bloom Science is a clinical-stage, central nervous system company, trailblazing a path to transformative, novel therapeutics for patients with rare and complex neurological disorders. Bloom’s proprietary discovery platform, IrisRx enables a fundamentally different approach to developing medicines by harnessing our expanding insight into the Gut-Brain Axis to design and develop therapeutics that target novel biology with superior safety profiles. The IrisRx platform unlocks the potential for developing multi-functional therapeutics from the most common cell type in the human body, gut commensal microbes while utilizing an expanding proprietary knowledge base to advance therapeutic candidates based on synthetic biology. Bloom Science is advancing a deep pipeline of programs, including Dravet syndrome, other rare epilepsies, Amyotrophic Lateral Sclerosis, and other neurodegenerative and cognitive disorders.


- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.